CorMedix Analyst Says Investors Could Be Further Rewarded

Core Insights - CorMedix Inc. announced that a large dialysis organization customer has begun ordering its DefenCath catheter lock solution, with implementation set for the second half of 2025, targeting at least 50% more patients than initially planned [1] - The company revised its second-quarter net sales guidance from $31 million to a range of $35 million to $40 million due to expected increased product usage by the customer [2] - DefenCath, approved by the FDA in 2023, aims to reduce the risk of catheter-related bloodstream infections in adults undergoing chronic hemodialysis [3] Financial Performance - CorMedix anticipates a modest revenue increase in June, with continued growth expected in the latter half of the year [2] - The company has priced a public offering of 6.6 million shares, expecting gross proceeds of approximately $85 million [4] Analyst Coverage - HC Wainwright initiated coverage on CorMedix with a Buy rating and a price forecast of $20, citing positive early results from DefenCath's launch [3] - Analyst Brandon Folkes expressed confidence that the real-world experience and ongoing studies will support a sustainable long-term revenue stream for DefenCath [3][4]